<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739476</url>
  </required_header>
  <id_info>
    <org_study_id>QUEPRO</org_study_id>
    <secondary_id>GRS1855/A/18</secondary_id>
    <secondary_id>17/1358</secondary_id>
    <secondary_id>2016-004117-27</secondary_id>
    <nct_id>NCT03739476</nct_id>
  </id_info>
  <brief_title>Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients</brief_title>
  <official_title>Controlled, Double-blind, Randomized Clinical Trial for Prophilaxis of Postoperative Delirium in High Risk Surgical Patients With Quetiapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Biomédica de Salamanca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grupo Español de Rehabilitación Multimodal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blinded Clinical trial to test efficacy of Quetiapine versus placebo in reducing&#xD;
      postoperative delirium in high risk surgical patients after three days of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates postoperative delirium in high risk surgical patients to know the&#xD;
      incidence of postoperative delirium in patients at risk, over 65 years, treated early with&#xD;
      prophylactic quetiapine versus placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the crisis SARS-COV-2 pandemic: recruitment of patients for the trial is stopped,&#xD;
    healthcare pressure generated, suspend the non-essential scheduled surgical activity and on&#xD;
    June 30, 2020 medication expired, funding has been exhausted.&#xD;
  </why_stopped>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">December 23, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>one arm treatment. one arm placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To Know the incidence of postoperative delirium in patients at risk, over 65 years, treated early with prophylactic quetiapine versus placebo.</measure>
    <time_frame>28 (± 2) days from the start of treatment in each patient.</time_frame>
    <description>Proportion of patients diagnosed with delirium (number of cases of delirium / total number of patients) within the first four days in both arms.&#xD;
65 years, treated early with prophylactic quetiapine versus placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days without delirium, if it appears.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Number of days from the start of treatment until delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of delirium, if it appears.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapine.</time_frame>
    <description>Number of days with delirium, if it appears. Perceived quality of life.&#xD;
Mortality (all causes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of delirium measured with a validated scale. time of appearance the duration and severity. use of another antipsychotics.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Severity of delirium measured with a the Delirium Rating Scale-Revised-98 (DRS-R-98).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of other antipsychotic (haloperidol).</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Total dose (mg) of other antipsychotic to control symptoms of delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of sedation.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Degree of sedation measured with a validated scale Richmond Agitation-Sedation Scale (RASS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of QTc prolongation.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Increased (msec) ECG control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of extrapyramidal symptoms.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Presence o absence of extrapyramidal symptoms (tremor, involuntary movements, rigidity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in hospital from surgery.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Number of days from surgery until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived general well-being.</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Evaluation of quality of life using Short Form-36 Health Survey questionnaire (SF36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (all causes)</measure>
    <time_frame>28 ± 2 days from the start (first dose) of treatment with quetiapin.</time_frame>
    <description>Mortality at discharge and at 28 (± 2) days before the start of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Postoperative Delirium</condition>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine 25 miligrames 1 hour after surgery and each 12 hours for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 hour after surgery and each 12 hours for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine 25 milligrams capsule</intervention_name>
    <description>Compare the incidence of postoperative delirium.</description>
    <arm_group_label>Interventional</arm_group_label>
    <other_name>Experimental arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Compare the incidence of postoperative delirium.</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than or equal to 65 years-old patients who will be undergoing major surgery&#xD;
             (noncardiac) and having an equal or greater score of 5 on the scale Delphi.&#xD;
&#xD;
          -  Age: 70-79 years: 1 point; ≥80 years: 2 points.&#xD;
&#xD;
          -  Physical activity: need for assistance, not self-sufficient: 2 point.&#xD;
&#xD;
          -  Alcoholism: 1 point.&#xD;
&#xD;
          -  Hearing Impaired: 1 point.&#xD;
&#xD;
          -  History of delirium: 2 points.&#xD;
&#xD;
          -  Emergency surgery: 1 point.&#xD;
&#xD;
          -  No laparoscopic surgery: 2 points.&#xD;
&#xD;
          -  Admission critical Units: 3 points.&#xD;
&#xD;
          -  Value of C-reactive protein (CRP)≥ 10 mg (milligrms) / dL (decilitre): 1 point&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to quetiapine.&#xD;
&#xD;
          -  Patients with a score less than 5 on the Delphi scale.&#xD;
&#xD;
          -  Diagnosis of delirium at admission.&#xD;
&#xD;
          -  Cardiological diseases: qtc ≥ 460 mseg (millisecond) in men, ≥ 470 msec (millisecond)&#xD;
             in women, recent MI or cardiac decompensation, 2-3 ° AV block or history of torsades&#xD;
             de pointes arrhythmias or ventricular arrhythmias, bradycardia...&#xD;
&#xD;
          -  Hypokalemia ≤ 3 mEq / CLK.&#xD;
&#xD;
          -  History of drug use.&#xD;
&#xD;
          -  Patients on Antipsychotic or antidopaminergic treatment (chlorpromazine, clozapine,&#xD;
             olanzapine, risperidone, haloperidol, quetiapine, paliperidone, amisulpride).&#xD;
&#xD;
          -  Parkinson's disease.&#xD;
&#xD;
          -  Test MINIMENTAL ≤ 24.&#xD;
&#xD;
          -  Corps or vascular dementia Levi.&#xD;
&#xD;
          -  Hypokinetic movement disorder.&#xD;
&#xD;
          -  History of neuroleptic malignant syndrome.&#xD;
&#xD;
          -  Central Anticholinergic Syndrome.&#xD;
&#xD;
          -  Epilepsy.&#xD;
&#xD;
          -  Patients with a wight less than 50 or greater than 200 kg (kilograms).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa Sanchez-Barrado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 18, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative</keyword>
  <keyword>Delirium</keyword>
  <keyword>Quetiapine</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

